PROK

1.0411.79%
TC

Todd C. Girolamo

Chief Legal Officer & Secretary

Mr. Todd C. Girolamo, J.D., Esq. M.B.A, serves as Chief Legal Officer at ProKidney Corp. since March 15, 2022 and also serves as its Corporate Secretary since 2024. He served as an Independent Director of Longeveron Inc. since February 15, 2022 until June 09, 2023. His experience includes Securities and Exchange Commission, stock exchange and Food and Drug Administration compliance, corporate finance, M&A and licensing activities. He has further experience with intellectual property, litigation and drug development. He served as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary at Caladrius Biosciences, Inc. since April 2021 until March 14, 2022 and also had been Senior Vice President, General Counsel since October 15, 2015 until April 2021. Mr. Girolamo was responsible for managing all legal aspects of the Caladrius' research and development pipeline, from preclinical research to multinational pivotal clinical trials, including academic and corporate collaborations. He was responsible for Caladrius' licensing activities, the strategy, maintenance and prosecution of the Caladrius' extensive global patent estate and the management of all litigation involving and its subsidiaries. He joined Caladrius in 2011. He served as Associate General Counsel at Caladrius Biosciences, Inc. since February 2011. Mr. Girolamo was in private legal practice at Am Law 100 law firms, served as director and managing director at various investment banks and was a portfolio manager and analyst at a long-short hedge fund. He is a seasoned attorney and biopharmaceutical executive specializing in health-related products and businesses. Mr. Girolamo began his legal career as an associate at Cahill Gordon & Reindel in 1990 and concluded his tenure in private practice at Reid & Priest, where he gained expertise as a general commercial litigator, practicing in the areas of intellectual property, securities law, employment law and bankruptcy. Along with over a decade of experience as both corporate counsel and a private practitioner, Mr. Girolamo served on Wall Street specializing in therapeutic healthcare equity securities with institutional equities as a series 24, 7 and 63 licensed Principal at Oppenheimer & Co., CIBC World Markets, Leerink Swann & Co. and Summer Street Research Partners where he specialized in equity research, sales and trading of biotechnology, pharmaceuticals and medical technology market sectors. Mr. Girolamo then served as an Analyst and portfolio Manager at Lion?s Path Capital managing a long-short portfolio of biopharma and med-tech equities. Mr. Girolamo received a Bachelor of Arts from Harvard College, a Juris Doctor from the University of Pennsylvania Law School and a Master of Business Administration from Columbia Business School.

Positions